title: Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
authors.affiliation: Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Hubert H
authors.initials: HH
authors.lastname: Fernandez
authors.affiliation: University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors.forename: David G
authors.initials: DG
authors.lastname: Standaert
authors.affiliation: AbbVie Inc, North Chicago, Illinois, USA.
authors.forename: Krai
authors.initials: K
authors.lastname: Chatamra
authors.affiliation: AbbVie Inc, North Chicago, Illinois, USA.
authors.forename: Janet A
authors.initials: JA
authors.lastname: Benesh
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D006801:Humans; D007422:Intestines / Q000502:physiology*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D005782:Gels; D007980:Levodopa; D002230:Carbidopa